TriangleNCT00411619 · CITED IN SOURCE DOCUMENTS
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE1, PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2014-10-20
The purpose of the study is to evaluate the safety and potential side effects of everolimus (an experimental drug) on a person with Tuberous Sclerosis Complex who also has been diagnosed with a brain tumor (astrocytoma) The hypothesis is that the drug will cause the tumor size to decrease, and may have beneficial activity separate from effects on tumors in patients.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Age three years and older * If female and of child bearing potential, documentation of negative pregnancy test prior to enrollment. In the extension phase, all females of child bearing potential will be required to take monthly home pregnancy tests and record results on a provided diary card. * Clinically definite diagnosis of tuberous sclerosis (modified Gomez criteria or positive genetic test) * Presence of giant cell astrocytoma as defined by imaging characteristics and serial increase in size of lesion on 2 or more MRI scans * Adequate renal function (creatinine \< 1.5 mg/dl) Exclusion Criteria: * Serious intercurrent medical illness or other uncontrolled medical disease which could compromise participation in the study * Significant hematologic or hepatic abnormality * Continuous requirement for supplemental oxygen * Intercurrent infection at initiation of everolimus * Embolization of angiomyolipoma within one month; any other recent surgery within 2 months of initiation of everolimus * Pregnant or lactating women * Use of an investigational drug within the last 30 days * Must be adequately recovered from the acute toxicities of any prior therapy * Clinical evidence of impending herniation or focal neurologic deficit related to the subject's astrocytoma * Unwilling or unable to use highly effective contraception
- healthy Volunteers
- false
- minimum Age
- 3 Years
- sex
- ALL
- std Ages
- CHILD
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- As this was a non-randomized, open-label, single arm study, all patients in the study received treatment with everolilmus
- intervention Names
- Drug: Everolimus
- label
- Everolimus
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Everolimus
- description
- Initial everolimus dosage will be 3 mg/m2/d taken daily or every other day, with titration to achieve a trough serum level of 5-15 ng/ml. Patients unable to tolerate levels in this range will have doses held or reduced 25% to achieve trough serum levels of 5-10 ng/ml. If trough serum level of 5-15 ng/ml is not achieved at a dosage of 3 mg/m2/d, then dosage escalation by 25% will be undertaken as tolerated. Everolimus will be similarly adjusted during the extension phase. If a subject misses more than 10 consecutive everolimus doses, additional days of everolimus treatment will be added so total duration of treatment is 6 months. If this occurs, dates of subsequent study events will be adjusted according to number of missed doses. This process will also be followed in the extension phase.
- name
- Everolimus
- other Names
- RAD001
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 28
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- measure
- Number With Observed Adverse Side Effects
- time Frame
- During the entire study
- secondary Outcomes
- measure
- Overall Reduction in SEGA Tumor Volume.
- time Frame
- During the entire study
Full study description
- brief Summary
- The purpose of the study is to evaluate the safety and potential side effects of everolimus (an experimental drug) on a person with Tuberous Sclerosis Complex who also has been diagnosed with a brain tumor (astrocytoma) The hypothesis is that the drug will cause the tumor size to decrease, and may have beneficial activity separate from effects on tumors in patients.
- detailed Description
- Tuberous Sclerosis Complex (TSC)is a genetic disorder with a birth incidence of approximately one in six thousand. Five to twenty percent of patients with TSC will develop astrocytoma, a slowly progressive tumor. They grow and cause damage to surrounding brain tissue, blockage of spinal fluid (hydrocephalus), blindness, trouble walking, seizures, and brain damage. If untreated, they can be fatal. Standard treatment involves surgery to remove the tumor; however surgery may itself cause brain damage, bleeding, or infection, as well as other complications. Studies have shown that everolimus suppresses the chemicals that cause tumors to grow in tuberous sclerosis, and may cause them to shrink. The primary objective of this study is to find out the effects of everolimus on astrocytomas in a six month trial in patients with Tuberous Sclerosis who have been diagnosed with an astrocytoma
Source references
- references
- citation
- Peters JM, Prohl A, Kapur K, Nath A, Scherrer B, Clancy S, Prabhu SP, Sahin M, Franz DN, Warfield SK, Krueger DA. Longitudinal Effects of Everolimus on White Matter Diffusion in Tuberous Sclerosis Complex. Pediatr Neurol. 2019 Jan;90:24-30. doi: 10.1016/j.pediatrneurol.2018.10.005. Epub 2018 Oct 18.
- pmid
- 30424962
- type
- DERIVED
- citation
- Sparagana S, Franz DN, Krueger DA, Bissler JJ, Berkowitz N, Burock K, Kingswood JC. Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex. PLoS One. 2017 Oct 12;12(10):e0186235. doi: 10.1371/journal.pone.0186235. eCollection 2017.
- pmid
- 29023494
- type
- DERIVED
- citation
- Franz DN, Agricola K, Mays M, Tudor C, Care MM, Holland-Bouley K, Berkowitz N, Miao S, Peyrard S, Krueger DA. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015 Dec;78(6):929-38. doi: 10.1002/ana.24523. Epub 2015 Nov 9.
- pmid
- 26381530
- type
- DERIVED
- citation
- Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 2013 Feb 5;80(6):574-80. doi: 10.1212/WNL.0b013e3182815428. Epub 2013 Jan 16.
- pmid
- 23325902
- type
- DERIVED
- citation
- Tillema JM, Leach JL, Krueger DA, Franz DN. Everolimus alters white matter diffusion in tuberous sclerosis complex. Neurology. 2012 Feb 21;78(8):526-31. doi: 10.1212/WNL.0b013e318247ca8d. Epub 2012 Jan 18.
- pmid
- 22262746
- type
- DERIVED
- citation
- Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010 Nov 4;363(19):1801-11. doi: 10.1056/NEJMoa1001671.
- pmid
- 21047224
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-81b7072edd7b3ecd3e0c
- requested nct id
- NCT00411619
- primary nct id
- NCT00411619
- source kind
- fda_spl_label
- source record id
- b808a4e0-23a8-40c8-834d-b31cd642febe
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 0898f80be424ace16389ecf48c89b558d15a51e081348c9ae355e00ed01db672
- payload
- application numbers
- NDA022334
- NDA203985
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-81b7072edd7b3ecd3e0c
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00411619
- occurrences
- context exact
- cumented disease progression by the end of the follow-up period and no patient required surgical intervention for SEGA during the study. Study 2485 Study 2485 (NCT00411619) was an open-label, single-arm trial conducted to evaluate the antitumor activity of AFINITOR 3 mg/m 2 /orally once daily in patients with SEGA and TSC. Serial
- end
- 21408
- exact text
- NCT00411619
- start
- 21397
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/20/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- b808a4e0-23a8-40c8-834d-b31cd642febe
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 292fd8bc940fa684e774f57a8a92cad85906d1749b134239bf692550e9588618
- spl effective time
- 20260601
- spl set id
- 2150f73a-179b-4afc-b8ce-67c85cc72f04
Preserved source evidence · Not medical advice